These issues may become even further accentuated 6 months or longer after the vaccination, as small titers of neutralizing antibodies disappear from the blood.
Furthermore, many people will develop immunity to this vaccine itself, which doesn’t relate to immunity against SARS.
Furthermore, many people will develop immunity to this vaccine itself, which doesn’t relate to immunity against SARS.
By using viruses to produce portions of another virus (in this case and Oxford’s case, an adenovirus to make spike proteins of SARS2), you also make it nearly impossible to repeatedly dose and administer a new vaccine when SARS2 mutates and evolves.
More details:
https://t.co/XwGzVrOCT6
https://t.co/XwGzVrOCT6
https://t.co/NTqzNgJsF2
Why does ACE2 binding affinity matter? Because SARS2 has such stickiness for ACE2, that the neutralizing antibody site actively cannot be bound to by maturing B cell receptors, and the resulting antibodies are also unlikely to mature into hyper-high-affinity ones.
The antibodies that do mature to be high affinity are going to be preferentially matured towards non-neutralizing sites, since the ACE2 competes for binding ~15x more strongly than ACE2 does with SARS1. It’s basic binding kinetics and thermodynamics, guys.
More details:
As far as I’m aware, @Ligandal is the only tech designed to eliminate this ACE2 binding from the viral spike protein, exposing the virus so that your immune system can make the proper antibodies.
https://t.co/rvJRm2LLwV
So, I ask, why isn’t @BARDA clearing funding for us? Why is the Pentagon (@PentagonPresSec?) not clearing DoD funding for an urgently needed, innovative antidote technology?
Ligandal is a DoD-cleared federal contractor. We have real technology. You are funding Moderna with $483M.
Ligandal is a DoD-cleared federal contractor. We have real technology. You are funding Moderna with $483M.
